[ad_1]
According to CNN, the preliminary results are much better than expected.
– A great day for science and humanity, write Pfizer and its partner BioNTech in a press release.
Health Director Bjørn Guldvog says 70-80 percent is a very high number.
– So this is good news, says Guldvog.
Pfizer’s vaccine is one of the candidates that may be available in the EU and Norway, if the vaccine is approved.
– Important step
The vaccine is currently in phase 3 testing. This means that the company is testing the vaccine in a larger group of people.
43,000 people are included in the study and have received the vaccine or a placebo. According to Pfizer, preliminary results show that less than 10 percent of corona infections were detected in people who had been vaccinated and more than 90 percent of infections were detected in people who had received a placebo for the vaccine.
“With today’s news, we are taking an important step in giving people around the world a much-needed breakthrough to help end this global health crisis,” Pfizer CEO Albert wrote on Monday. Bourola, in a press release.
Denmark report: “Very urgent”
– Such good news
The company hopes to be able to apply for an urgent approval in the US as early as November, writes CNN. They hope to be able to offer around 50 million doses of the vaccine in 2020 and up to 1.3 billion doses in 2021.
– Stock markets are rising, the vaccine is coming soon. Reported 90 percent effective. Good news! Outgoing President Donald Trump wrote on Twitter shortly after the news broke.
The president has repeatedly claimed that a vaccine is just around the corner, several times that it should be ready before the presidential election on Tuesday last week.
However, the results Pfizer released Monday do not mean a vaccine is imminent. Preliminary results are based on just 94 infections that have so far been recorded among 44,000 people in the US and other countries, NTB writes.
Ten companies hoping to develop a functional corona vaccine are currently in phase three testing. However, Pfizer and BioNTech are the first to present preliminary results from this phase, writes BBC.
